Orthocell Ltd has released a press release.
Regulatory Approval to Commence Sales for Striate in Canada
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Orthocell
- Record Quarterly and Yearly Revenue Show Outstanding Growth
- Third Revenue Generating Product to be Launched in SmrtGraft
- Orthocell reports 98.6% success rate in Striate+â„¢ dental membrane study
- Outstanding 98.6% Success Rate in Striate Implant Study
- Orthocell receives $3.05m R&D tax incentive refund
Later from Orthocell
- Company Presentation
- First sales of Striate in major new market of Canada
- Second Consecutive Record Quarter as Revenue Exceeds $2m
- Regulatory approval to commence Remplir sales in Singapore
- $17m Placement to Drive Further Growth as US Approval Nears
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell